This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

This study has been completed.
Information provided by (Responsible Party):
Robert Negrin, Stanford University Identifier:
First received: September 13, 2005
Last updated: December 13, 2012
Last verified: December 2012
The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).

Condition Intervention
Acute Disease Myelodysplastic Syndromes Leukemia, Myeloid, Chronic Myeloproliferative Disorders Blood and Marrow Transplant (BMT) Myelodysplastic Syndromes (MDS) Leukemia Procedure: ablative allogeneic hematopoietic cell transplantation

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide

Resource links provided by NLM:

Further study details as provided by Robert Negrin, Stanford University:

Primary Outcome Measures:
  • tolerability
  • efficacy of therapy

Secondary Outcome Measures:
  • compare efficacy of this treatment to historical controls

Estimated Enrollment: 120
Study Start Date: September 1992
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CIK cell
The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.
Procedure: ablative allogeneic hematopoietic cell transplantation

Detailed Description:
To learn whether a new preparative regimen to prepare patients for bone marrow transplantation is useful in patients above 50 years of age and whether it is useful in patients with myelodysplastic syndromes.

Ages Eligible for Study:   51 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:1) Patients aged 51-60 with acute non-lymphocytic leukemia in first or subsequent remission and acute lymphocytic leukemia in first remission with high risk features which include elevated white blood cell count at presentation, cytogenetic abnormalities, extramedullary leukemia, ALL in greater than first remission and patients with chronic myelogenous leukemia at any stage who have a histocompatible sibling donor.

2) Patients with myelodysplastic syndrome including patients with refractory anemia with excess blasts or refractory anemia with excess blasts in transformation.

3) Patients with myeloproliferative disorders which give them poor long-term disease-free survival, such as myeloid metaplasia or myeloid fibrosis.

4) Patients with secondary myelodysplasia following cytotoxic chemotherapy.

Exclusion Criteria:- Organ dysfunction

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00186342

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Robert S Negrin Stanford University
  More Information

Responsible Party: Robert Negrin, Professor of Lymphatic Research and Medicine, Stanford University Identifier: NCT00186342     History of Changes
Other Study ID Numbers: BMT45
Study First Received: September 13, 2005
Last Updated: December 13, 2012

Additional relevant MeSH terms:
Myelodysplastic Syndromes
Myeloproliferative Disorders
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Acute Disease
Pathologic Processes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Disease Attributes processed this record on September 20, 2017